Theravance - THRX Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Theravance - THRX

THRX 9.810

+0.4%

Jan 8 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tom pope	6/26/2007 8:59:12 AM
	Read Replies (1) of 74

Merrill: Price Objective Changes Theravance Inc (THRX, US$31.32, C-1-9) Reiterate Buy; Raise PT to $40 from $37 based on a higher probability of success for TD-5108. Theravance reported positive phase II data for TD-5108 to treat chronic constipation. We are expecting several key catalysts by YE07. We expect phase II data for TD-1792 in serious skin infections during the summer, potential opt-in for TD-5108 by GSK within 60-90 days, potential opt-in for TD-1792 by Astellas, potential approval for telavancin to treat serious skin infections in Oct., and phase III telavancin data for hospital-acquired pneumonia, which could double the drug’s market.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next